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Although high serum levels of galactose-deficient IgA1 (an
important biomarker of IgA nephropathy (IgAN)) are found
in most patients with IgAN, their relationship to disease
severity and progression remains unclear. To help clarify this
we prospectively enrolled 275 patients with IgAN and
followed them for a median of 47 months (range 12–96
months). Serum galactose–deficient IgA1 was measured at
the time of diagnosis using a lectin-based ELISA, and renal
survival was modeled using the Cox proportional hazards
method. The serum levels of galactose-deficient IgA1 were
higher in patients with IgAN compared to those in healthy
controls. Importantly, in adjusted analysis, higher levels
of galactose-deficient IgA1 were independently associated
with a greater risk of deterioration in renal function with
a hazard ratio of 1.44 per standard deviation of the natural
log–transformed galactose-deficient IgA1 concentration.
In reference to the first quartile, the risk of kidney failure
increased such that the hazard ratio for the second quartile
was 2.47, 3.86 for the third, and 4.76 for the fourth quartile
of the galactose-deficient IgA1 concentration. Hence,
elevated serum levels of galactose-deficient IgA1 are
associated with a poor prognosis in IgAN.
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IgA nephropathy (IgAN) is the most common form of
primary glomerulonephritis worldwide1 and the leading
cause of end-stage renal disease (ESRD) in young adults.2
The pattern of glomerular immunoglobulin deposits is
suggestive of an immune complex–mediated mechanism.3–7
Multiple studies have established the contribution of
aberrantly glycosylated IgA1 in the pathogenesis of IgAN.8–12
IgA1 is one of the very few serum proteins with
O-glycosylation. The O-glycans in the hinge region of normal
IgA1 consist of N-acetylgalactosamine, galactose, and sialic
acid. In patients with IgAN, some of the O-glycans of
circulating IgA1 are deficient in galactose. Similarly, mesan-
gial immune deposits eluted directly from glomeruli
of IgAN patients contained galactose-deficient IgA1
(Gd-IgA1).7,13,14 On the basis of the potential pathogenic
role of Gd-IgA1 in the development of IgAN, a quantitative
assay for serum Gd-IgA1 holds promise as a non-invasive
diagnostic tool. We previously reported an increased binding
of a N-acetylgalactosamine-specific lectin from Helix
aspersa (HAA) to desialylated serum Gd-IgA1 in Caucasian
patients with IgAN.15 Our earlier study demonstrated
that Gd-IgA1 was also closely associated with the pathologic
phenotype of IgAN.16 However, it is not known whether
elevated levels of Gd-IgA1 in sera of IgAN patients are
associated with accelerated disease progression, or a worse
prognosis.17
We have previously established a large prospective cohort
of patients with IgAN followed regularly at the Peking
University Institute of Nephrology. This cohort has been
assembled and followed as part of the Peking University
IgAN database project since 2003 (http://www.renal-online.
org), with blood and urine samples collected at the
time of kidney biopsy, and clinical data collected prospec-
tively for all enrolled patients. In this study, we utilize the
above resource to examine the prognostic utility of serum
levels Gd-IgA1.
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RESULTS
Baseline clinical, laboratory, and pathological data
Among the 275 IgAN patients, there were 147 (53.5%) males
and 128 (46.5%) females with mean age at the time of kidney
biopsy of 32.7±10.7 years. On biopsy, average proteinuria
level was 1.92±1.89 g per 24 h (range 0.01–13.72 g/24 h) and
average estimated glomerular filtration rate (eGFR) was
82.65±27.44 ml/min per 1.73 m2 (range 6.3–164.9 ml/min
per 1.73 m2). Systolic blood pressure was 124±16 mm Hg,
diastolic blood pressure 79±12 mm Hg, with 131 patients
(47.6%) being hypertensive at baseline. The distribution by
Haas grade I, II, III, IV, and V was 10.9%, 0.4%, 32.4%,
42.9%, and 13.5%, respectively. The median follow-up time
was 47 months (range 12–96 months; Table 1). During the
follow-up period, 266 (96.7%) patients received ACE
inhibitors or ARBs therapy, 127 (46.2%) received oral
corticosteroids alone or combined with other immunosup-
pressive agents. In total, 42 patients reached the composite
end point of 50% decline in eGFR (n¼ 39), ESRD (n¼ 3), or
death (n¼ 2; both had a 50% decline in eGFR before death).
Serum Gd-IgA1 levels
HAA-based enzyme-linked immunosorbent assay (ELISA)
for Gd-IgA1 was highly reproducible (r¼ 0.903, Po0.0001).
The level of Gd-IgA1 in IgAN patients (median: 312.5 U/ml,
interquartile range (IQR) 236.5–407.8 U/ml) was signifi-
cantly higher compared with that of the healthy controls
(148.3 U/ml, IQR 106.1–209.1 U/ml, Po0.001). The patients
were next divided into four equal groups according to the
quartiles of the Gd-IgA1 distribution; group 1: serum Gd-IgA1
levels o236.5 U/ml; group 2: serum Gd-IgA1 between 236.5
and 312.5 U/ml; group 3: serum Gd-IgA1 between 312.5 and
407.8 U/ml; and Group 4: serum Gd-IgA1 4407.8 U/ml.
Among cases, we observed no significant association of
Gd-IgA1 levels with age, gender, or body mass index (BMI;
Table 2). There was a trend for lower eGFR, higher proteinuria,
and increased use of immunosuppressives in groups 3 and 4
compared with groups 1 or 2, albeit none of these differences
were statistically significant. There were also no significant
differences between the groups in the blood pressure control
(P¼ 0.96) or proteinuria during follow-up (P¼ 0.94).
Association of Gd-IgA1 with kidney disease progression
Baseline clinical and pathological variables were tested for
association with the primary progression outcome using Cox
proportional hazards model. In univariate analyses, lower
baseline eGFR, higher histological grading, greater degree of
proteinuria, use of steroids, and higher levels of Gd-IgA1
were all significantly associated with a progression risk, but
age, gender, hypertension, hemoglobin, or albumin levels
were not (Supplementary Table S1 online).
Unadjusted and multivariable adjusted hazard ratios
(HRs) for composite of end point are presented in Table 3
according to baseline Gd-IgA1, expressed as a continuous
variable or in quartiles. In adjusted analysis including
baseline proteinuria, hypertension, eGFR, Haas classification,
and steroid therapy, higher levels of Gd-IgA1 were indepen-
dently associated with a greater risk of kidney failure (HR,
per s.d. of natural log–transformed Gd-IgA1 1.44; 95%
confidence interval (CI), 1.11–1.88, P¼ 0.006). Gd-IgA1 level
remained strongly associated with progression even after
adjustment for time-average proteinuria and other baseline
risk factors including hypertension and eGFR (HR¼ 1.39,
95% CI 1.24–1.56, P¼ 1.15 108). Compared with the first
quartile of Gd-IgA1 (reference), the risk of kidney failure
increased by quartile of Gd-IgA1 level: the HRs were 2.47
(95% CI, 0.91–6.72) for the second quartile, 3.86 (95% CI,
1.33–11.33) third quartile, and 4.76 (95% CI, 1.61–14.09)
fourth quartile.
As shown in Figure 1, the renal survival deteriorated by
the quartile of serum Gd-IgA1 level. The renal survival at first
and third year in each group of patients was 100.0% and
96.9%; 100.0% and 91.8%; 100.0% and 92.2%; 98.6% and
88.6%, respectively (log-rank test, P¼ 0.004).
We also analyzed Gd-IgA1/IgA1 ratio and Gd-IgA1/
total IgA ratio instead of Gd-IgA1. Gd-IgA1/IgA1 and
Table 1 | Baseline clinical and laboratory data and levels of
serum Gd-IgA1 in 275 patients with IgAN
Characteristics
Mean±s.d. (range or
percentage)
Age (year) 32.7±10.7 (15–76)
Gender (male) 147/275 (53.5%)
SBP (mmHg) 124±16
DBP (mmHg) 79±12
Hypertension (%)a 131/275 (47.6%)
Initial proteinuria (g/day) 1.92±1.89
o0.3 (%) 15/275 (5.5%)
0.3–0.99 (%) 84/275 (30.5%)
1.0–2.99 (%) 130/275 (47.3%)
X3.0 (%) 46/275 (16.7%)
eGFR (ml/min per 1.73m2) 82.65±27.44
Stages 1, 2, 3, and 4 CKD (KDOQI)b 125 (45.7%), 92 (33.3%),
50 (18.0%), 8 (3%)
Follow-up interval (month, median, IQR) 47 (30–60)
Gd-IgA1 (U/ml, median, IQR) 312.5 (236.5–407.8)
Total IgA (mg/ml, median, IQR) 2630.0 (2125.0–3510.0)
Plasma IgA1 (mg/ml, median, IQR) 1709.9 (1376.2–2159.7)
Therapy (%)
ACE inhibitors or ARBs 96.7
Prednisone 46.2
Any other immunosuppressive agents
(cyclophosphamide, MMF, or others)
29.8
Histological grading (%)c
I, II, III, IV, V 30 (10.9%), 1 (0.36%), 89 (32.4%),
118 (42.9%), 37 (13.5%)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor
blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimate
glomerular filtration rate; Gd-IgA1, galactose-deficient IgA1; IgAN, IgA nephropathy;
IQR, interquartile range; MMF, mycophenolate mofetil; SBP, systolic blood pressure.
aHypertension was defined as SBP of greater than 140mmHg, and/or DBP of greater
than 90mmHg at resting, or use of anti-hypertension medication.
bCKD stage 1, 2, 3, and 4 were divided by eGFRX90, 60–89, 30–59, and 15–29,
respectively.
cHistological grading was classified according to pathological scheme proposed by
Haas.45
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Gd-IgA1/IgA ratios also represented risk factors for kidney
disease progression in the univariate analysis (unadjusted
HR¼ 1.42, 95% CI 1.05–1.92, P¼ 0.021; and HR¼ 1.56, 95%
CI 1.15–2.12, P¼ 0.005, respectively) but were not signifi-
cantly associated after adjustment for other covariates in the
multivariate model (P¼ 0.2 and 0.34, respectively).
DISCUSSION
IgAN can have a highly variable course. Some patients
progress rapidly to ESRD, whereas others have a rather
benign disease trajectory.17,18 The individual outcomes of
IgAN remain difficult to predict. Previous longitudinal
studies have associated proteinuria, hypertension, and
impaired renal function at the time of diagnosis with IgAN
progression.19 In this study, we hypothesize that the increased
serum level of Gd-IgA1, the key pathogenic feature in IgAN,
causes accelerated disease progression in IgAN.
On the basis of the comparison of Gd-IgA1 levels between
the IgAN patients and a large group of healthy population
controls, our study confirmed that serum Gd-IgA1 levels are
elevated in IgAN. Most importantly, our study also demon-
strated that high levels of Gd-IgA1 were predictive of renal
function decline in IgAN. On the basis of our prospective
follow-up data, we found that elevated level of serum Gd-
IgA1 was independently associated with increased risk of
renal disease progression. Among cases with biopsy-based
diagnosis of IgAN, participants with the highest vs. the lowest
quartile demonstrated a 4.76-fold greater risk of kidney
progression. Thus, our data suggest that high levels of Gd-
IgA1 may have prognostic utility in IgAN. Our observations
Table 2 | Baseline data of clinical features and levels of serum Gd-IgA1 of four groups defined by quartiles of serum Gd-IgA1
1 2 3 4
U/ml, median (IQR) U/ml, median (IQR) U/ml, median (IQR) U/ml, median (IQR)
Group 193.9 (158.4, 213.8) 272.5 (247.2, 289.0) 345.7 (324.2, 369.9) 487.4 (438.8, 540.3) P value
Number 69 69 68 69
Gender (male) 41/69 37/69 33/68 36/69 0.638
Age (year) 32.78±11.43 33.87±10.63 32.47±11.3 31.80±9.34 0.718
Hypertension (%) 34 (49.3%) 34 (49.3%) 27 (39.7%) 36 (52.2%) 0.488
Proteinuria (%, 41g/day) 42/69 (60.9%) 39/69 (56.5%) 50/68 (73.5%) 45/69 (65.2%) 0.196
eGFR (ml/min per 1.73m2), stages
1, 2, 3, and 4 CKD (KDOQI)
29/28/10/2 34/18/16/1 29/24/13/2 30/22/13/4 0.715
Histological grading (mild lesions/severe
lesions)
26/43 29/40 34/34 31/38 0.525
Prednisone 27 (39.13%) 29 (42.03%) 37 (54.41%) 34 (49.28%) 0.264
Any other immunosuppressive agents 21 (30.4%) 18 (26.1%) 16 (23.5%) 24 (34.7%) 0.481
ACE inhibitors or ARBs 68 (98.60%) 69 (100.0%) 66 (97.10%) 64 (94.10%) 0.157
Total IgA (mg/ml, median, IQR) 2026 (1566.5,2411) 2479 (2309.5,2849) 2880 (2362.5,3669) 3483 (2855,4012) o0.001
Plasma IgA1 (mg/ml, median, IQR) 1352.2 (1138.3,1699.7) 1574.7 (1325.9,1827.6) 1868.8 (1556.8,2289.6) 2109.5 (1765.5,2558.6) o0.001
Kidney failure events (%) 6 (8.69%) 6/69 (8.69%) 15/68 (22.1%) 15/69 (21.7%) 0.026
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; eGFR, estimate glomerular filtration rate; Gd-IgA1,
galactose-deficient IgA1; IQR, interquartile range.
Histological grading was divided into mild lesions and severe lesions group. The former group included Haas I, II, and III, and the latter group included IV and V. Continuous
data were compared by one-way analysis of variance test; dichotomous or categorical data were analyzed by w2 test.
Table 3 | Risks of composite end-point natural log–transformed Gd-IgA1 and ascending quartiles
Hazard ratio (95% confidence interval) and P-value
Gd-IgA1, median (range), U/ml Unadjusted Model 1a Model 2b Model 3c
Composite end point
Per 1 s.d. lnGd-IgA1 312.5 (89.0–1442.0) 2.07 (1.53–2.78) 1.51 (1.16–1.97) 1.50 (1.15–1.96) 1.44 (1.11–1.88)
1.68 106 0.002 0.003 0.006
Gd-IgA1 quartiles
1 193.88 (89.0–237.0) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
2 272.51 (239.0–312.0) 2.63 (0.94–7.36) 2.71 (0.99–7.39) 2.73 (0.99–7.45) 2.47 (0.91–6.72)
0.066 0.052 0.051 0.077
3 345.67 (313.0–406.0) 4.03(1.36–11.96) 3.74 (1.28–10.93) 3.72 (1.27–10.89) 3.86 (1.33–11.33)
0.012 0.016 0.016 0.013
4 487.36 (408.0–1442.0) 6.76 (2.23–20.19) 5.18 (1.75–15.34) 5.29 (1.78–15.73) 4.76 (1.61–14.09)
0.001 0.003 0.003 0.005
Abbreviations: Gd-IgA1, galactose-deficient IgA1; lnGd-IgA1, natural log–transformed Gd-IgA1.
aModel 1 adjusted for estimate glomerular filtration rate (eGFR), proteinuria, and hypertension (yes or no). Hypertension (yes or no) was analyzed as dichotomous data.
bModel 2 adjusted for covariates in model 1 plus histological grading (mild and severe lesion group). The latter variable was analyzed as categorical data.
cModel 3 adjusted for covariates in model 2 plus steroid use (yes or no). The latter variable was analyzed as dichotomous data.
Composite end point was defined as 50% decline of eGFR (n=29), end-stage renal disease (n=3), or death (n=2). The two deaths also had 50% decline of eGFR. Unadjusted
model analyzed Gd-IgA1 as continuous data.
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that individuals with higher levels of Gd-IgA1 are more prone
to disease progression may justify closer follow-up and
possibly more aggressive treatment of such individuals.
A recent study from Japan found that Gd-IgA1 was also
significantly elevated in Japanese IgAN patients,20 however,
this study did not examine its impact on kidney disease
progression. Another study investigated the impact of
Gd-IgA1 levels on the renal function decline rate among 62
Caucasian patients with IgAN.21 Gd-IgA1 was independently
associated with proteinuria level during the follow-up.
Although Gd-IgA1 by itself was not associated with the rate
of GFR decline, the combination of a high level of Gd-IgA1
and advanced oxidation protein products contributed to a
more rapid loss of renal function. However, the small sample
size was the major limitation of the prior studies. Taken
together, these studies suggest that aberrant glycosylation of
IgA1 contributes to the risk of nephropathy in both Chinese
and Caucasian populations.
Both in vivo and in vitro studies have now firmly
established that altered O-glycosylation of serum IgA1 has a
central role in the development of IgAN.22–24 Novak et al.
have demonstrated that B-cell abnormal expression/activity
of enzymes involved in sialylation and/or galactosylation of
the IgA1 hinge region O-linked glycans underlie this defect.
Furthermore, anti-glycan antibodies (IgG and/or IgA1)
recognize Gd-IgA1 (auto-antigen) and trigger the formation
of IgA1-containing immune complexes.5 In addition, it
appears that the defect in the glycosylation of IgA1 is, to a
large degree, genetically determined.25–27 However, this IgA1
O-glycosylation aberrancy (Hit 1) itself is not sufficient to
induce renal injury.25 Synthesis and binding of antibodies
directed against Gd-IgA1 are required for the formation of
immune complexes that accumulate in the glomerular
mesangium (Hits 2).28 On the basis of the results of this
study, we speculate that a higher level of circulating Gd-IgA1,
when exposed to the second hit, may result in more severe
kidney injury.
The limitations of our study include the relatively short
follow-up, with a median ofB4 years. This reduces the study
power, with fewer end points observed during this time
period. We used a composite end point of 50% decline from
baseline eGFR, ESRD, or death, which is a robust outcome
used in many clinical trials.29 Future extension of this study
to a follow-up period that exceeds 10 years would enable
examination of harder end points (such as ESRD alone) and
provide more accurate effect estimates. Other limitations
stem from the complicated multistep ELISA assay used in this
study to quantify Gd-IgA1 levels. This method may not be
ideal for accurate detection of small differences in Gd-IgA1
levels. Mass spectrometry–based methods, such as those30–33
developed recently may be more appropriate future ap-
proaches. In addition, the observed distribution of serum
Gd-IgA1 levels deviates from normality and is positively
skewed. To circumvent this problem, we used quartiles of Gd-
IgA1 levels in our regression analyses. Finally, we recognize
that our results may not be applicable to all patient
populations, as our study cohort consists of only Han
Chinese patients followed at a single tertiary care medical
center. Additional longitudinal studies of more diverse
patient cohorts are needed to validate our findings.
Patients with IgAN are characterized by a highly variable
clinical course ranging from a totally benign incidental
condition to rapidly progressive renal failure. Many studies
have focus on predicting outcomes in IgAN from the baseline
clinical or pathological variables.19,20,34–37 In the French
cohort with subjects followed over an average of 13 years,
Berthoux et al. proposed a comprehensive scoring system
based on the number of risk factors such as hypertension,
proteinuria, and severe pathological lesions to predict the
long-term dialysis or death in patients with IgAN.35 Another
scoring system that was developed from a large Japanese
multicenter study with more than 2000 patients and 10-year
follow-up, the risk factors to predict long-term renal
outcomes included age, sex, family history of kidney disease,
proteinuria, hypoalbuminuria, mild hematuria, low GFR,
and a high histological grade.36 The recent Oxford classifica-
tion of IgAN identified pathological variables of prognostic
significance for disease progression.37 A set of four kidney
lesions, the MEST score (M, mesangial hypercellularity; E,
endocapillary proliferation; S, segmental glomerulosclerosis/
adhesion; T, tubular atrophy/interstitial fibrosis) was closely
associated with kidney failure independent of clinical
assessment, which was also validated in other studies.38–40
Our study has suggested that measurement of baseline Gd-
IgA1 can be used as an additional variable and improve
power of these prediction systems in IgAN.
As in other studies, baseline proteinuria, kidney function,
and pathological lesions are also risk factors for disease
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Figure 1 |Renal survival in IgA nephropathy (IgAN) patients
with four quartile serum galactose-deficient IgA1 (Gd-IgA1)
levels. The renal survival deteriorated by the quartile of serum
Gd-IgA1 level. The time zero was kidney biopsy. The division
between the four groups of patients was based on quartile of Gd-
IgA1 level expressed as 236.5, 312.5, and 407.8 U/ml. The renal
survival at the first and third year in each group of patients was
100.0% and 96.9%; 100.0% and 91.8%; 100.0% and 92.2%; and
98.6% and 88.6%, respectively (log-rank test, P¼ 0.004).
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progression. However, in this study we did not find baseline
hypertension associated with kidney failure. This may be due
to the small sample size or few end point events to detect the
difference. Another possible explanation is that these data are
from a prospective database, and blood pressure was well
controlled. Several prospective studies have also observed the
same phenomenon.41–43
In summary, this is the first study to demonstrate that
elevated Gd-IgA1 levels in Asian patients with IgAN may
affect disease progression. Further studies are needed to
determine whether Gd-IgA1 levels change in the course of
disease or respond to specific treatment regimens, and
whether these factors alter the overall prognosis in IgAN.
MATERIALS AND METHODS
Patients and healthy controls
This study includes 275 patients with IgAN diagnosed from renal
biopsy. All enrolled patients had been followed for a minimum of
12 months (range 12–96 months). The diagnosis was based upon
the demonstration, by immunofluorescence, of IgA as the dominant
or co-dominant immunoglobulin in mesangial deposits, as well
as the lack of clinical or serological evidence of other inflammatory
conditions, such as systemic lupus erythematosus, vasculitis, or
Henoch–Schoenlein purpura. Complete clinical data, including age,
gender, systolic/diastolic blood pressure, serum creatinine, total
serum IgA, and 24-h total protein excretion were collected at the
time of renal biopsy. The composite end point in this study was
defined by a 50% decline in eGFR from the time of diagnosis ESRD
or death, whichever occurred first. For the purpose of this study,
ESRD was defined as eGFR o15 ml/min per 1.73 m2 or need for
renal replacement therapy (such as hemodialysis, peritoneal dialysis,
or renal transplantation). The eGFR was calculated using the
Modification of Diet in Renal Disease formula.44 All renal biopsy
specimens were reviewed and graded by an independent pathologist
who was blinded to patients’ outcomes. The histological lesions were
classified as grade I–V as proposed by Haas when patients
participated in this study.45 Haas grading I–III were classified as
mild lesions, and IV and V as severe lesions. Hypertension was
defined as systolic blood pressure of 4140 mm Hg, and/or diastolic
blood pressure of 490 mm Hg at resting, or use of anti-hyperten-
sion medication. All the patients receive a same therapy regimen
including optimal blood pressure control target of o130/80 mm
Hg, RAS inhibition and steroids, or other immunosuppressive
agents for patients with persistent proteinuria. The blood pressure
and proteinuria control were expressed as time-average mean artery
pressure or time-average proteinuria.43
The healthy population controls consisted of 499 residents of the
same geographical area matched by age and gender with the IgAN
patients. The healthy controls consisted of 342 males and 157
females. The mean age was 32.4±8.7 years. All individuals
were at least 18-year-old (range 19–55 years). The Institutional
Review Boards at the Peking University First Hospital approved this
study. Written informed consent was obtained from all study
participants.
Detection of serum IgA and Gd-IgA1 by ELISA
Sera from patients, collected before renal biopsy, and from healthy
controls were aliquoted and stored at 20 1C until the time of
assays. Serum IgA and Gd-IgA1 were quantified by ELISA, according
to a protocol established earlier.15 Briefly, high-binding MaxiSorp
96-well plates (Nalge-Nunc, Rochester, NY) were coated overnight
with 2.5 mg/ml F(ab0)2 fragment of goat anti-human IgA (Jackson
ImmunoResearch Labs, West Grove, PA) in phosphate-buffered
saline (PBS). The coated plates were blocked with 1% bovine serum
albumin (Sigma Chemical Company, St Louis, MO) in PBS-0.05%-
Tween 20. Duplicates of two-fold dilutions of serum samples and
standards were added and the plates were incubated overnight at
room temperature. The sample dilutions ranged from 1:80,000 to
1:2,560,000 for total IgA, from 1:10,000 to 1:40,000 for plasma IgA1,
and from 1:2000 to 1:16,000 for Gd-IgA1. To quantitate the total
IgA, a standard consisting of a pool of normal human sera,
previously calibrated for immunoglobulin isotype concentration
(Binding Site, Birmingham, UK), was used at concentrations
between 25 ng/ml and 0.195 ng/ml. For the measurement of plasma
IgA1, a standard consisting of native IgA1 purified by normal
human plasma (EMD Chemicals, Gibbstown, NJ) was used at
concentrations between 500 ng/ml and 0.686 ng/ml. For the
measurement of Gd-IgA1, the standard consisting of a polymeric
Gd-IgA1 protein.12 isolated from a patient with multiple myeloma
was used. To determine the galactose-deficient glycans on IgA1, the
terminal sialic acid from O-linked N-acetylgalactosamine on bound
samples and the standard IgA1 myeloma protein were removed by
incubation with 1 mU/well neuraminidase (Roche Diagnostic,
Indianapolis, IN) in 0.01 mol/l acetate buffer pH 5 for 3 h at
37 1C.6 After washing, 100ml biotin-labeled HAA (1:500 dilution;
Sigma) was added to each well and incubated for 3 h at 37 1C. The
total IgA was detected by incubation with biotin-labeled F(ab0)2
fragment of goat IgG anti-human IgA (BioSource, Camarillo, CA)
for 3 h at 37 1C. Total level of IgA1 was determined by incubation
with affinipure F(ab0)2 fragment goat anti-human serum IgA
(Jackson ImmunoResearch Labs) at 4 1C over night. After washing,
100 ml mouse anti-human monoclonal antibody (1:50,000 dilution;
Sigma) was added to each well and incubated for 1 h at 37 1C. For
IgA, total IgA1, and Gd-IgA1, the plates were further incubated with
horseradish peroxidase-ExtrAvidin (Sigma) for 1 h at 37 1C. The
plates were then developed with the peroxidase chromogenic
substrate o-phenylenediamine–H2O2 (Sigma). The color reaction
was stopped with 1 mol/l sulfuric acid and the absorbance was
measured at 490 nm with an EL312 Bio-Kinetics microplate reader
(Bio-Tek Instruments, Winooski, VT). The amounts of total IgA and
Gd-IgA1 in the tested samples were calculated with the DeltaSoft II
program (BioMetallics, Princeton, NJ) by interpolating the optical
densities on calibration curves, constructed using serum IgA and a
Gd-IgA1 myeloma protein. The results for total IgA were expressed
as mg/ml. As the standard IgA1 myeloma protein is not entirely
devoid of galactose, the expression of results in mg/ml does not
precisely reflect the concentration of Gd-IgA1 in the sera. Therefore,
we expressed the results in U/ml. One unit of Gd-IgA1 was defined
as 1 mg of this standard Gd-IgA1 myeloma protein.15 To assess the
degree of intra-assay variability, the HAA-ELISA was repeated with
108 randomly selected patients samples.
Statistical analyses
Summary statistics for normally distributed quantitative variables
were expressed as means and standard deviations. For non-normally
distributed variables, we used median and IQR; categorical data
were summarized by ratios and percentages. Differences in means
for continuous variables were compared using Student’s t-test (two
groups) or analysis of variance (multiple groups), and differences in
proportions were tested by w2 test. Cox proportional hazards
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models were used to analyze the association of serum Gd-IgA1 levels
and the primary outcome. Gd-IgA1 was highly skewed to the right
in this group patients and natural log transformation was used.
Serum Gd-IgA1 was first analyzed as a continuous variable with HRs
calculated per s.d. increment of natural log–transformed Gd-IgA1,
and the Gd-IgA1 quartile as a categorical variable, with the
lowest quartile defined as the reference group. The relationship
between Gd-IgA1 and risk of end point was examined in unadjusted
and multivariable-adjusted Cox models. Proportional hazards
assumptions were verified by testing the interaction of survival
time and lnGd-IgA1 and quartiles of Gd-IgA1 (P¼ 0.23 and
P¼ 0.17, respectively), and by inspecting parallelism of estimated
hazard functions. A two-sided P-value o0.05 was considered
statistically significant. All statistical tests were performed using
SPSS version 16.0 (SPSS, Chicago, IL).
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